Stifel lowered the firm’s price target on Zoetis to $180 from $195 and keeps a Buy rating on the shares. The firm believes Q1 top-line will modestly exceed consensus, but it lowered its 2025 operational revenue growth and EPS estimates to 5.5% and $6.29 from 6.6% and $6.45, respectively, noting that the Street is calling for 7.1% and $6.47 for those metrics. The “crux of the call” is the trajectory of Librela into 2025, added the firm, which believes potential headwinds may soon surface attributable to consumer safety concerns.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZTS:
- Zoetis price target lowered to $200 from $205 at BofA
- Zoetis to sell medicated feed additive portfolio to Phibro Animal Health
- Zoetis price target lowered to $230 from $260 at Barclays
- Jefferies cuts Zoetis target, says vet survey positive for Librela
- Scout Clean Energy announces 12-year VPPA with Zoetis
